Blog
RSS FeedPosted by Michael Wonder on 22 Oct 2020
$10,000 on new drugs every four months keeps melanoma patient alive
21 October 2020 - Graham Venning was given “weeks perhaps months” to live at the start of the year but ...
Posted by Michael Wonder on 21 Oct 2020
Priority review granted to Ascentage Pharma's new drug application for olverembatinib (HQP1351), the first third generation BCR-ABL inhibitor in China
21 October 2020 - Ascentage Pharma today announced that the Center for Drug Evaluation of China's National Medical Products Administration has ...
Posted by Michael Wonder on 21 Oct 2020
NICE recommended use of Opdivo for another indication
20 October 2020 - This marks the tenth NICE recommendation for nivolumab. ...
Posted by Michael Wonder on 21 Oct 2020
TG Therapeutics announces fast track designation granted by the FDA to ublituximab in combination with umbralisib for the treatment of adult patients with chronic lymphocytic leukaemia
21 October 2020 - TG Therapeutics today announced that the U.S. FDA has granted fast track designation to the combination of ...
Posted by Michael Wonder on 21 Oct 2020
‘It really seems cruel’: drug giant’s brutal blow to Australian breast cancer patients
21 October 2020 - Terminally ill breast cancer patients will have to pay $1,600 a month for a lifesaving treatment, after ...
Posted by Michael Wonder on 20 Oct 2020
Tagrisso granted priority review in the US for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
20 October 2020 - Unprecedented results show treatment with Tagrisso reduced the risk of disease recurrence or death by 80% in ...
Posted by Michael Wonder on 19 Oct 2020
U.S. Food and Drug Administration accepts for priority review applications for Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) in advanced renal cell carcinoma
19 October 2020 - U.S. Food and Drug Administration assigned a target action date of 20 February 2021. ...
Posted by Michael Wonder on 19 Oct 2020
Bristol Myers Squibb receives positive CHMP opinion recommending Opdivo (nivolumab) as second-line treatment for unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma
16 October 2020 - Application based on Phase 3 ATTRACTION-3 trial demonstrating a statistically significant and clinically meaningful improvement in patients’ ...
Posted by Michael Wonder on 18 Oct 2020
First CAR-T cell medicine for mantle cell lymphoma
16 October 2020 - EMA has recommended granting a conditional marketing authorisation in the European Union for Tecartus (autologous anti-CD19 ...
Posted by Michael Wonder on 17 Oct 2020
Health Canada approves Keytruda (pembrolizumab) as first-line treatment for patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma
15 October 2020 - Approval Based on Significant Overall Survival Findings from Phase 3 KEYNOTE-048 Trial. ...
Posted by Michael Wonder on 17 Oct 2020
Venclexta (venetoclax) receives FDA full approval for acute myeloid leukaemia
16 October 2020 - The FDA approval of Venclexta for newly diagnosed AML patients who are ineligible for intensive chemotherapy is ...
Posted by Michael Wonder on 15 Oct 2020
EMA cancer symposium: new approaches in patient-focused cancer medicine development
15 October 2020 - On Thursday, 29 October, EMA is hosting a symposium to discuss new approaches to facilitating and ...
Posted by Michael Wonder on 15 Oct 2020
FDA approves expanded indication for Merck’s Keytruda (pembrolizumab) in adult patients with relapsed or refractory classical Hodgkin lymphoma
15 October 2020 - Keytruda is the first anti-PD-1 therapy approved for adult patients with relapsed or refractory classic Hodgkin lymphoma ...
Posted by Michael Wonder on 14 Oct 2020
Scotland backs two myeloma drugs turned down by NICE in England
14 October 2020 - A north-south divide threatens to emerge in multiple myeloma in the UK, after the Scottish Medicines ...
Posted by Michael Wonder on 14 Oct 2020
CTI BioPharma initiates rolling submission of new drug application for pacritinib in myelofibrosis patients with severe thrombocytopenia
13 October 2020 - Completion of submission expected in first quarter 2021. ...